Summary of Frontier Bio's 2025 Semi-Annual Report
Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceuticals (Nanjing) Co., Ltd. Company Code: 688221 Company Abbreviation: Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceuticals (Nanjing) Co., Ltd.
August 2025
Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceutical (Nanjing) Co., Ltd.
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to www.sse.com.cn to read the full text of the semi-annual report carefully.
1.2 Major risk warning
The company's 2025 semi-annual report contains forward-looking statements that involve significant risks and uncertainties. The Company's forward-looking statements are primarily based on the Company's current expectations and forecasts of future events and trends, which the Company believes may affect the Company's business, financial condition and results of operations. Except for historical information, all statements in the 2025 semi-annual report are forward-looking statements. These statements involve risks and uncertainties, including those described under "IV. Risk Factors" in "Section 3 Management Discussion and Analysis" of the "Full Text of the 2025 Semi-annual Report", which may cause actual performance and results to be materially different from those expected. In light of the above uncertainties, investors should not place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information or otherwise, except as otherwise required by law.
1.3 The company’s board of directors, board of supervisors and directors, supervisors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
1.4 All directors of the company shall attend the board meeting.
1.5 This semi-annual report has not been audited.
1.6 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
Not applicable
1.7 Whether there are any important matters such as special arrangements for corporate governance
□Applicable √Not applicable
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Company Stock Profile
Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change Shanghai Stock Exchange Section
A shares Frontier Biotech 688221 Not applicable
GEM
Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceutical (Nanjing) Co., Ltd.
Company Depository Receipts Brief Introduction
□Applicable √Not applicable
Contact person and contact details
Contact person and
Secretary of the Board of Directors (Domestic Representative for Information Disclosure) Securities Affairs Representative
Contact information
Name Gao Qianya Bao Lina
Phone 025-69648375 025-69648375
Office address 11th floor, Building E-2, Greenland Window, Dongshan Street, Jiangning District, Nanjing City 11th floor, Building E-2, Greenland Window, Dongshan Street, Jiangning District, Nanjing E-mail [email protected] [email protected]
2.2 Main financial data
Unit: Yuan Currency: RMB
The end of the reporting period is higher than the end of the previous year. The end of the reporting period is higher than the end of the previous year.
Increase or decrease(%)
Total assets 1,663,227,898.40 1,812,138,179.73 -8.22 Attributable to listed company shares
1,043,975,542.62 1,141,311,396.90 -8.53 Dong’s net assets
This reporting period increased compared with the same period last year. The reporting period increased compared with the same period last year.
Less(%)
Operating income 58,639,825.88 51,056,036.51 14.85 Total profit -97,352,610.68 -160,459,078.15 Not applicable Attributable to shares of listed companies
-97,352,610.68 -160,459,078.15 Not applicable to Dong’s net profit
Attributable to listed company shares
Net profit after deducting non-recurring items -114,735,072.42 -175,774,131.51 Not applicable to profit or loss
Cash generated from business activities
-98,227,841.69 -89,191,498.22 Not applicable Net cash flow
weighted average net assets
-8.91 -12.71 Increased 3.80 percentage points profit rate (%)
Basic earnings per share (yuan/
-0.26 -0.43 (not applicable to stocks)
Diluted earnings per share (yuan/
-0.26 -0.43 (not applicable to stocks)
R&D investment accounts for operating income
81.75 142.39 Proportion of income reduced by 60.64 percentage points (%)
2.3 List of shareholdings of the top 10 shareholders
Unit: Total number of shareholders (households) as of the end of the reporting period 12,046 Total number of preference shareholders (households) with voting rights restored as of the end of the reporting period 0 Total number of shareholders (households) holding shares with special voting rights as of the end of the reporting period 0
Shareholding status of the top 10 shareholders
Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceutical (Nanjing) Co., Ltd.
Holding includes transfer
shareholding
Shareholding Restriction clause Lending shares Pledge, mark or freeze shareholder name Nature of shareholder Ratio
Number of pieces of restricted shares Number of shares settled (%)
Number of shares Number of shares
Jianmu Pharmaceutical Co., Ltd. Overseas legal person 18.86 70,638,750 0 0 None 0 Overseas natural
LU RONGJIAN 5.80 21,743,750 0 0 None 0 people
Overseas nature
WANG CHANGJIN 5.62 21,059,500 0 0 None 0 people
Nanjing Jianmu Business Consulting Co., Ltd.
Others 4.59 17,200,000 0 0 None 0 partnership (limited partnership)
Beijing Wanlong Private Equity Fund Management
Management Co., Ltd. - Wanlong Capital
Others 3.78 14,160,000 0 0 None 0 New Era No. 21 Private Placement Certificate
securities investment funds
Nanjing Jianmu Biotechnology has domestic non-national
3.72 13,922,500 0 0 None 0 Co., Ltd. Legal person
Nanjing Yuhang Chunhua Enterprise Management
Others 2.48 9,290,000 0 0 None 0 Management Center (Limited Partnership)
Liaoning 3SBio Biopharmaceutical Investment Co., Ltd.
capital fund management partnership
(Limited partnership) - Liaoning San Others 1.58 5,915,000 0 0 None 0 Health Medical Industry Investment Fund
Partnership (limited partnership)
JO Cocolo Limited Overseas legal person 0.93 3,500,000 0 0 None 0 Domestic natural
Tang Huanxin 0.88 3,300,086 0 0 None 0 people
Jianmu Pharmaceutical Co., Ltd., Nanjing Jianmu Business Consulting Partnership (Limited
Partnership), Nanjing Jianmu Biotechnology Co., Ltd., and Nanjing Yuhang Chunhua Enterprise manage the related relationships or concerted actions of the above shareholders
Management Center (Limited Partnership) is controlled by DONG XIE, the actual controller of the company. Company description
It is unknown whether other unrestricted shareholders have related relationships or are listed under the
Persons acting in concert as stipulated in the "Company Acquisition Management Measures".
Preference shareholders with restored voting rights and shareholdings
Not applicable
Description of quantity
2.4 Table of the top ten domestic depositary receipt holders
□Applicable √Not applicable
2.5 Table of top ten shareholders by number of voting rights as of the end of the reporting period
□Applicable √Not applicable
2.6 The total number of preference shareholders and the top 10 preference shareholders as of the end of the reporting period
□Applicable √Not applicable
Summary of the 2025 Semi-Annual Report of Frontier Biopharmaceutical (Nanjing) Co., Ltd.
2.7 Changes in controlling shareholders or actual controllers
□Applicable √Not applicable
2.8 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable